Uncategorized

Aardvark to dig into phase 3 data early after FDA imposes hold

Aardvark Therapeutics is planning to unblind data from its phase 3 Prader-Willi syndrome program after the FDA put a full clinical hold on its studies.​Read More

Published

on

Aardvark Therapeutics is planning to unblind data from its phase 3 Prader-Willi syndrome program after the FDA put a full clinical hold on its studies.​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version